Abstract:Hyperkalemia is a common metabolic problem in patients with chronic kidney disease. Although oral medications and hemodialysis are clinically applied for lowering serum potassium, the intrinsic limitations encourage alternative therapy in the trend of adsorbent-based miniaturized blood purification devices. Cells serve as the biological K+ storage units that accumulate K+ through multiple mechanisms. Inspired by cells, our strategy aims at favorable permeation and enrichment of K+ in the microsphere. We incorporate cation-affinitive groups into core-shell structures with submicron-sized phase separation. These nano-spaced side-groups cooperate to form interlinked clusters, where crown ethers with Angstrom-scale ring for size-matched complexation, while ionic sulfonic acid groups for hydrophilicity and charge-buffering. The unique structure with such non-covalent interactions facilitates K+ for permeation across the shell and binding to the core while also ensuring mechanical strength and anti-swelling durability in biofluids. The microspheres exhibit high selectivity ratios of K+ (SK/Na, SK/Ca, SK/Mg up to 9.8, 21.6, and 17.7). As column adsorbents for hemoperfusion simulation, they effectively lower elevated K+ levels to the normal range (clearance rates up to 44.4%/45.3% for hyperkalemic human serum/blood). Blood compatibility tests show low protein adsorption, preferable hemocyte compatibility, and anticoagulation property in vitro. This promising strategy has clinical potential for hyperkalemia in high-risk patients. STATEMENT OF SIGNIFICANCE: Hyperkalemia (serum potassium >5 mmol/L) is a common complication in chronic renal failure patients. The limitations of existing treatments prompt a shift to wearable artificial kidney technology for clinical convenience and efficacy. Existing treatments have limitations, and we turn to adsorbent-based miniaturized blood purification devices in the prospect of wearable artificial kidney technology. There exists a lack of ion-specific adsorbents applied in extracorporeal circuits to redress electrolyte imbalances like hyperkalemia. Inspired by cells, we aim at the favorable permeation and enrichment of K+ by microspheres. The microspheres have a microphase-isolated core-shell structure, whose nano-spaced groups form cation-affinitive clusters. Selective K+ removal and blood compatibility are achieved. We expect this strategy to enlighten alternative hyperkalemia therapy for these high-risk patients.

Nouveautés dans la prise en charge de l’hyperkaliémie

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…

Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders

Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials

Tailoring treatment of hyperkalemia

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease

Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]

Hyperkalemia in CKD: an overview of available therapeutic strategies

Hyperkalemia: Pharmacotherapies and Clinical Considerations

Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

Hyperkalemia treatment standard

Consensus document on the management of hyperkalemia

Selective potassium uptake via biocompatible zeolite–polymer hybrid microbeads as promising binders for hyperkalemia

Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial

Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials

Cell-inspired selective potassium removal towards hyperkalemia therapy by microphase-isolated core-shell microspheres

Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and opportunities

Calcium polystyrene sulfonate in treating hyperkalemia patients with chronic kidney disease: a multi-center clinical study

Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?

Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis